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A B S T R A C T
Background. Acute kidney injury (AKI) is a common complication after cardiac surgery and 
percutaneous coronary interventions which markedly worsens prognosis. In recent years, 
new early biomarkers of AKI have been identified, but many important aspects still remain 
to be solved. Klotho is a pleiotropic protein that acts as a paracrine and endocrine factor in 
multiple organs. Reduced renal Klotho levels have been show in several animal models of 
AKI. No study has been published in which Klotho was tested in humans as an early marker 
of AKI. The aim of this work is to assess the usefulness of measuring urinary Klotho for the 
early diagnosis of AKI in patients with acute coronary syndrome or heart failure undergoing 
cardiac surgery or coronary angiography. Methods. Urinary Klotho was measured 12 hours 
after intervention in 60 patients admitted to the Intensive Care Unit with acute coronary 
syndrome or heart failure secondary to coronary or valvular conditions, who underwent 
coronary angiography (30 patients) or cardiac bypass surgery or heart valve replacement (30 
patients). The primary endpoint used was the onset of AKI according to the RIFLE classification 
system. Human Klotho levels were measured using an ELISA assay. 
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prevented or treated by means of early interventions12. New 
early biomarkers of AKI, such as NGAL (Neutrophil Gelatinase-
Associated Lipocaline), KIM-1 (Kidney Injury Molecule 1), 
L-FABP (Liver Fatty Acid-Binding Protein), Cystatin C or IL-18 
(Interleukin 18), have been identified in recent years, but 
many important aspects remain to be solved in the search for 
the ideal biomarker13. The study of these molecules has also 
provided a greater understanding of AKI pathogenesis.
The Klotho gene was identified in 1997 as an anti-aging 
gene14. This gene is expressed in multiple tissues, the kidney 
being the organ where it is expressed more markedly,15 espe-
cially in the distal tubule, but also in the proximal tubule16 
and the collecting duct17,18. Klotho is a transmembrane pro-
tein that acts as a co-receptor for fibroblast growth factor-23 
(FGF-23)19,20. The ectodomain may be cut and released into 
the extracellular space by the proteases anchored to ADAM10 
and ADAM1721 membrane. This results in soluble Klotho, 
Introduction
Acute kidney injury (AKI) is a common complication following 
cardiac surgery and percutaneous coronary interventions, 
with an estimated incidence around 30% in the former1-3 and 
between 5 and 20% in the latter4-6. The onset of AKI signifi-
cantly worsens prognosis in these patients2,3,7. AKI increases 
mortality in different clinical contexts and, additionally, 
patients often develop chronic kidney disease (CKD) after 
AKI8-9. The mechanisms involved in AKI include both endog-
enous and exogenous toxins, metabolic factors, ischaemia 
and reperfusion, neurohumoral activation, inflammation and 
oxidative stress10. The diagnosis of AKI is based on detecting 
increased serum creatinine, which occurs late and does not 
adequately reflect the glomerular filtration in acute patients11. 
However, experimental studies show that AKI can only be 
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Results. We found no differences in urinary Klotho levels between AKI patients and those 
who did not develop AKI. Moreover, there was not significant correlation between urinary 
Klotho levels and the presence of AKI. Conclusion. Urinary Klotho measured by ELISA does 
not seem to be a good candidate to be used as an early biomarker of AKI.
© 2015 Sociedad Española de Nefrología. Published by ELSEVIER ESPAÑA, SLU. Published 
under the terms of the CC BY-NC-ND Licence(http://creativecommons.org/licenses/
by-nc-nd/4.0).
Klotho urinario determinado por ELISA como biomarcador precoz 
de fracaso renal agudo en pacientes sometidos a cirugía cardiaca 
o angiografía coronaria
R E S U M E N
Introducción y objetivos: El fracaso renal agudo (FRA) es una complicación frecuente tras la 
cirugía cardiaca y las intervenciones percutáneas coronarias cuya aparición empeora el 
pronóstico de manera marcada. En los últimos años se han identificado nuevos biomarcadores 
precoces de FRA, pero aún quedan muchos aspectos importantes por resolver. Klotho es una 
proteína pleiotrópica que actúa como un factor paracrino y endocrino en múltiples órganos. 
En diversos modelos animales de FRA se ha demostrado niveles disminuidos de Klotho renal. 
No se ha publicado ningún estudio en el que se haya probado Klotho como marcador precoz 
de FRA en humanos. El objetivo de este trabajo es investigar la utilidad de la determinación 
de Klotho en orina para el diagnóstico precoz del FRA en pacientes con síndrome coronario 
agudo o fallo cardiaco sometidos a cirugía cardiaca o angiografía coronaria. 
Métodos: Se midió Klotho urinario 12 horas tras la intervención en 60 pacientes ingresados en 
la unidad de cuidados intensivos por síndrome coronario agudo o fallo cardiaco secundarios 
a enfermedad coronaria o valvular y a los que se realizó angiografía coronaria (30 pacientes) 
o cirugía cardiaca de recambio valvular o bypass (30 pacientes). El criterio de valoración 
primario fue la aparición de FRA según la clasificación RIFLE. Los niveles de Klotho humano 
se midieron utilizando un ensayo ELISA. 
Resultados: No encontramos diferencias en los niveles de Klotho en orina entre los pacientes 
que desarrollaron FRA y aquellos que no. Además, no había correlación significativa entre 
niveles de klotho en orina y presencia de FRA. 
Conclusión: Klotho urinario medido por ELISA no parece ser un buen candidato para ser usado 
como biomarcador precoz de FRA.
© 2015 Sociedad Española de Nefrología. Publicado por ELSEVIER ESPAÑA, SLU. Publicado 
bajo los términos de la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
by-nc-nd/4.0).
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of AKI, defined as an increase of creatinine of 50% or more 
based on the RIFLE (Risk, Injury, Failure, Loss, End-stage renal 
disease) classification44. This study was approved by the 
Hospital Clínico Universitario de Valencia Ethics Committee 
and it was conducted in compliance with the principles of the 
Declaration of Helsinki45. 
Processing of urine samples
Urine samples were centrifuged for 10 minutes at 1500 g 
immediately after being collected, and the supernatant was 
stored in 0.5-mL aliquots at –80ºC for later use. 
Measurement of urinary Klotho levels
Human Klotho levels were determined in urine, both in 
patients and in controls, using two commercial ELISA assays: 
one from Shanghai Sunred Biological Technology Co., Ltd, 
which is present in blood, cerebrospinal fluid22 and urine23. 
There is another soluble Klotho protein which is shorter, but 
its function is not well known24. Soluble Klotho is a pleiotro-
pic protein that acts as a paracrine and endocrine hormonal 
factor, both in the kidney and in other organs25. In the renal 
tubule, Klotho modulates sodium-phosphate cotransport-
ers23, calcium channels26 and potassium channels27. Finally, 
Klotho is also present at nuclear and cytoplasmic levels, 
where it functions as an anti-aging protein28,29.
Klotho’s role in aging and in phosphocalcic metabolism 
continues to become more understood16,30,31. Its implications 
in the progression of CKD and its non-renal complications 
have also been the focus of intense study in recent years25,32-
34, as well as the relationship existing among its circulating 
levels, glomerular filtration and CKD prognosis35 or its poten-
tial use as an anti-fibrotic agent36. With respect to AKI, the 
presence of decreased Klotho levels has been shown in vari-
ous animal models of AKI induced by ischaemia-reperfusion, 
ureteral obstruction or nephrotoxic agents23,37-43. In 2010, Hu 
et al.23 measured urinary Klotho in 17 AKI patients and found 
decreased levels compared to the values obtained in 14 
healthy volunteers. No other studies have been published 
about Klotho as an AKI biomarker in humans. The objective 
of this paper was to assess the usefulness of measuring uri-
nary Klotho for the early detection of AKI in patients with 
acute coronary syndrome or heart failure undergoing cardiac 
surgery or coronary angiography.
Methods
Patients
Sixty patients were enrolled from a cohort of 193 patients 
admitted to the intensive care unit (ICU) of the Hospital 
Clínico Universitario de Valencia with acute coronary syn-
drome (ACS) or heart failure secondary to coronary or valvu-
lar disease. All patients had undergone coronary angiography 
with or without angioplasty or cardiac surgery. The coronary 
angiography group was made up of 30 patients: 18 had AKI 
after the intervention and 12 did not. Another 30 patients 
were also selected in the cardiac surgery group: 15 with AKI 
and 15 without AKI (Table 1).
The exclusion criteria were: age younger than 18 years; 
CKD on replacement therapy and AKI secondary to cardio-
genic shock during hospitalisation. All patients were prospec-
tively monitored since their enrolment in the study. Serum 
creatinine was measured from before the procedure up to six 
days after it, and the clinical progress of each patient was 
monitored until discharge. The first value of serum creatinine 
obtained on admission was used as the baseline creatinine 
value. Urine samples for Klotho measurement were collected 
12 hours after the intervention and processed immediately 
thereafter. We also obtained urine samples from 10 healthy 
volunteers to determine the normal values. Additionally, the 
following information was collected from each patient: demo-
graphic variables and comorbidities, parameters of the sur-
g ical procedure and complicat ions dur ing or af ter 
interventions (Table 1). The primary endpoint was the onset 
Table 1 – Clinical and demographic characteristics  
of patients
Non-AKI 
patients
AKI 
patients
Coronary angiography
No. of patients 12 18
Age (years) 63 ± 15 72 ± 10
Sex (M/F) 8/4 14/4
Baseline eGFR (MDRD)  
(mL/min/1.73m2)
78 ± 15 60 ± 18**
Baseline creatinine (mg/dL) 0.93 ± 0.23 1.16 ± 0.27*
Maximum creatinine (mg/dL) 0.94 ± 0.23 1.99 ± 0.61***
AKI (day) 4 ± 2
RIFLE (R/I/F) 12/5/1
Hospital stay (days) 13 ± 11 17 ± 13
Deaths 0 4
CARDIAC SURGERY
No. of patients 15 15
Age (years) 68 ± 9 67 ± 15
Sex (M/F) 10/5 13/2
Baseline eGFR (MDRD)  
(mL/min/1.73m2)
60 ± 16 62 ± 29
Baseline Creatinine (mg/dL) 1.15 ± 0.37 1.18 ± 0.51
Maximum creatinine (mg/dL) 1.26 ± 0.35 2.14 ± 0.71***
AKI (day) 3 ± 1
RIFLE (R/I/F) 10/5/0
Hospital stay (days) 17 ± 10 27 ± 24
Deaths 0 4
Type of surgery
Bypass 10 4
Valvular 4 10
Bypass and valvular 1 1
Time on ECC (min) 62 ± 19 98 ± 57*
AKI: Acute kidney injury; baseline eGFR (MDRD): glomerular 
filtration rate estimated by MDRD before the intervention; AKI 
(day): day of AKI diagnosis by serum creatinine; Time on ECC: time 
of extracorporeal circulation in minutes; Values are expressed as 
mean ± SD; Values from AKI patients that differ significantly from 
non-AKI patients are expressed with *p < 0.05; **p < 0.01; ***p < 0.001.
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than patients who did not develop AKI in both groups of 
patients, although the differences were non-significant. In 
the angiography group, pre-intervention serum creatinine 
was significantly higher (p < 0.05) in AKI patients than in non-
AKI patients, whereas the baseline estimated glomerular fil-
tration rate (eGFR) was significantly lower in AKI patients (p 
< 0.01). No significant differences were found in these values 
in the group of patients with cardiac surgery (Table 1). In this 
group, the patients who developed AKI had been on extracor-
poreal circulation (ECC) for a longer period (p < 0.05) than 
patients who did not develop AKI (Table 1).
Urinary Klotho values
Urinary Klotho protein levels were significantly elevated in 
AKI patients both in the angiography group and the cardiac 
surgery group, when compared to the control group (p < 0.05) 
(Table 2). When correcting Klotho concentrations based on 
urine creatinine levels, only the AKI patients from the surgery 
group differed from the controls (p < 0.01), but there were no 
significant differences with respect to non-AKI patients (Table 
2). If the patients from both groups are considered together, 
urinary Klotho levels (corrected for creatinine) were signifi-
cantly higher in AKI patients than in healthy controls (p < 
0.05), but there were no significant differences compared to 
non-AKI patients (Table 2). A correlation was not found 
between Klotho levels and the presence of AKI (r = 0.182, p = 
0.67) when the Spearman’s test was conducted. Additionally, 
we examined whether there was a correlation between the 
Klotho level (ng/mg of urine creatinine) and delta serum cre-
atinine (maximum serum creatinine – baseline creatinine) for 
both ELISA assays. No significant correlations were found 
when the patients from both groups were considered together 
or separately, regardless of the assay used.
There was no significant correlation between urinary 
Klotho levels (ng/mL) measured by the two ELISA assays (r = 
–0.079; p = 0.614) or after correction based on urine creatinine 
(r = –0.043; p = 0.792).
with a sensitivity of 0.05 ng/mL and an assay range of 0.1–20 
ng/mL, and the other assay from IBL International (Human 
soluble a-Klotho Assay Kit – IBL, Immuno-Biological 
Laboratories Co., Ltd), with a sensitivity of 0.006 ng/mL and 
an assay range of 0.093–6 ng/mL. The values obtained were 
adjusted to urine creatinine. Creatinine was measured in 
serum and urine using standard techniques. 
Statistical analysis 
We analysed our results with GraphPad PRISM (version 4.0) 
software. A Kolmogorov-Smirnov test was conducted to ver-
ify that the variables followed a normal distribution. For the 
comparison of means with more than two variables, a 
one-factor ANOVA was performed with a post-hoc Bonferroni 
analysis, and for the comparison of two means, a Student’s 
or Mann-Whitney test was used in case of non-normal distri-
bution. The correlations between the presence of AKI and 
urinary Klotho levels were conducted by Spearman’s correla-
tion. The correlations between the Klotho levels measured 
with the two ELISA assays, and between the Klotho level (ng/
mg creatinine) and the serum delta creatinine (maximum 
serum creatinine – baseline creatinine), were conducted by 
Pearson’s bivariate correlation, with the SPSS vs. 19 analysis 
program. The significance level was set at p < 0.05.
Results
Patients characteristics
The clinical and demographic characteristics of patients are 
shown in Table 1. The diagnosis of AKI using creatinine 
required 3 ± 1 days in cardiac surgery patients and 4 ± 2 days 
in angiography patients. With respect to mortality, eight 
patients died: four from the cardiac surgery group and the 
other four from the angiography group, all of whom had 
developed AKI. AKI patients had a mean hospital stay longer 
Table 2 – Urinary Klotho values using two commercial ELISA kits
Parameter Control (n = 10) Angiography Cardiac surgery Angiography + Cardiac surgery
Non-AKI  
(n = 12)
AKI  
(n = 18)
Non-AKI 
(n = 15) 
AKI 
(n = 15)
Non-AKI 
(n = 27)
AKI 
(n = 33)
ELISA kit (Sun Red Biotechnologies)
Klotho (ng/ml) 1.80 ± 0.04 1.87 ± 0.05 1.94 ± 0.05* 1.80 ± 0.08 1.97 ± 0.04* 1.85 ± 0.04 1.96 ± 0.03
Klotho (ng/mg creatinine) 1.37± 0.24 2.12 ± 0.38 2.40 ± 0.45 2.00 ± 0.23 2.51 ± 0.21** 2.04 ± 0.20 2.45 ± 0.26*
ELISA Kit (IBL International)
Klotho (ng/ml) 0.77 ± 0.18 1.24 ± 0.34 1.51 ± 0.25 1.34 ± 0.36 1.25 ± 0.33 1.29 ± 0.25 1.38 ± 0.15
Klotho (ng/mg creatinine) 0.62 ± 0.05 1.23 ± 0.20 1.53 ± 0.30 1.25 ± 0.25 1.70 ± 0.30* 1.24 ± 0.30 1.60 ± 0.30
Values are expressed as mean ± SEM. The results are analysed by one-factor ANOVA with Bonferroni post-hoc analysis. Values from patients 
that are significantly different from the control group are indicated as: *p < 0.05; **p < 0.01; NON-AKI: Patients who did not develope acute 
kidney injury; AKI: Patients who developed acute kidney injury
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do not reflect Klotho expression well at renal tissue level. 
We know that the circulating levels do not relate to the 
expression in renal tissue in CKD. Data from animal exper-
imentation clearly indicate the existence of Klotho deficit at 
renal level in CKD48. However, the measurement of Klotho 
protein in plasma provides dissimilar results. Hu et al.48 
found very low Klotho levels in renal tissue, plasma and 
urine in mice with CKD, whereas Sugiura et al.49 found ele-
vated levels in plasma from patients with CKD. Devaraj et 
al.50 reported decreased levels in diabetic patients and high 
levels in CKD patients and, furthermore, those values cor-
related with plasma creatinine. They hypothesised that the 
Klotho protein could be synthesised at an extrarenal level 
to provide renal protection by anti-oxidant and anti-inflam-
matory mechanisms. Nevertheless, Seiler et al.35 measured 
plasma Klotho levels in a cohort of 312 patients with Stage 
2–4 CKD and did not find a correlation with glomerular fil-
tration. Plasma Klotho levels did not correlate with renal 
function and did not predict progression in patients with 
CKD. It is possible that, in patients with AKI, the Klotho pro-
tein is also being synthesised at the extrarenal level to pro-
vide renal protection and that it is appearing in the urine 
due to the glomerular filtration. Hu et al.23 and Moreno et 
al.40 found decreased Klotho levels in plasma from animal 
models of AKI. So far, no study has measured Klotho in 
plasma from humans with AKI. Even if Klotho levels were 
not increased in plasma, it is possible that it could be syn-
thesised at the extrarenal level and pass into urine. 
Therefore, plasma or urine levels may not reflect what is 
going on at tissue level. Further studies would be required 
to clarify this issue.
Obviously, another possible explanation for the results is 
the existence of methodological differences. To obtain more 
robust results, two different human ELISA kits from different 
manufacturers were used to measure urinary Klotho levels, 
but no differences were found in patients with or without 
acute kidney injury using either kit. The little consistency 
between both assays is also notable. It is possible that differ-
ent assays recognise different parts of the molecule and that 
some assays recognise the entire molecule while others rec-
ognise fragments. Heijboer et al.51 assessed three different 
ELISA assays, including the IBL one, and found major quality 
differences among them, IBL being clearly superior to the 
other two evaluated assays.
Conclusion
Despite the evidence in animal experimentation that Klotho 
is underexpressed in the kidney after either toxic or isch-
aemic AKI, in this study we did not find any correlation 
between the presence of AKI and urinary Klotho levels 12 
hours after the intervention in a group of patients admitted 
to the ICU for acute coronary syndrome or heart failure who 
had undergone cardiac surgery or coronary angiography, 
either with or without angioplasty or stenting. Although these 
results need to be confirmed, urinary Klotho measured by 
ELISA does not seem to be a good candidate to be used as an 
early biomarker of AKI.
Discussion
In this study, we assessed the usefulness of measuring Klotho 
protein in urine samples by ELISA for the early (12 hours 
post-intervention) detection of AKI in a group of patients with 
acute coronary syndrome or heart failure who had undergone 
cardiac surgery or coronary angiography, either with or with-
out angioplasty or stenting. We found no significant differ-
ences in Klotho levels between the patients who developed 
AKI and those who did not. We also found a small but signif-
icant increase in urinary Klotho levels in AKI patients follow-
ing cardiac surgery compared to healthy control subjects. The 
Klotho protein was measured in urine with two different 
ELISA kits for human Klotho. 
In the literature, there are no other studies testing urinary 
Klotho as an early biomarker of AKI in humans. There is only 
one study23 in which urinary Klotho was measured in 17 AKI 
patients by immunoblotting using anti-Klotho antibodies, and 
the authors reported decreased Klotho in AKI patients com-
pared to 14 healthy controls, although the urine samples were 
collected at a late stage of renal failure progression. It has 
been shown in animal models that Klotho is underexpressed 
in the renal tissue in AKI secondary to ischaemia-reperfusion, 
ureteral obstruction, sepsis or nephrotoxic agents23,37-43, and 
that the overexpression of the transmembrane protein or the 
administration of soluble protein has a protective effect 
against the renal damage induced by ischaemia and reperfu-
sion23,28 or nephrotoxins42. In 2010, Hu et al.23 measured 
Klotho expression in renal tissue as well as the levels of 
Klotho protein in plasma and urine in an animal model of 
ischaemia/reperfusion-induced AKI and found that Klotho 
was decreased at all levels.
We had already studied the usefulness of different bio-
markers as early predictors of AKI in this cohort of patients 
and had shown that NGAL46,47 was a strong predictor. Based 
on the evidence obtained in animal models of AKI, we 
expected to find decreased levels of Klotho protein in the 
urine of patients with AKI. There are several explanations 
for these dissimilar results. Firstly, all the experiments have 
been conducted in rats and mice. It is obvious that animal 
experiment conditions are not comparable to those in a clin-
ical context and that the results obtained cannot be directly 
extrapolated. Moreover, it is possible that Klotho protein 
does not behave in the same manner in humans as in animal 
models. Another possible explanation lies in sample collec-
tion time. Hu et al.23 found decreased Klotho levels in urine 
one day after ischaemia-reperfusion, but in our study the 
samples were collected 12 hours after the intervention. They 
also measured urinary Klotho in 17 patients with AKI and 
found that the levels were much lower than those obtained 
from healthy volunteers. However, the population in their 
study was very heterogeneous (including prerenal AKI and 
sepsis-induced AKI, lupus, obstruction, liver failure, trans-
plantation, uremic haemolytic syndrome and pregnancy) 
and data about the sample collection time were not pro-
vided. Notwithstanding, when the samples were collected, 
serum creatinine was 3.76 ± 0.58 mg/dL, so they were col-
lected very late. It is also possible that urinary Klotho levels 
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